DCGI Orders Withdrawal of Olaparib for Some Cancer Treatments

In a significant move by the Drug Controller General of India (DCGI), a directive has been issued to drug regulators across all states and Union territories, mandating the withdrawal of AstraZeneca's anti-cancer drug, Olaparib tablets, for specific cancer treatments. This decision impacts patients who have undergone three or more prior lines of chemotherapy for gBRCA mutation and advanced ovarian and breast cancer, citing potential adverse effects as the primary concern. However, it's important to note that Olaparib can still be marketed for other approved indications.

The communication, dated May 16, outlines that AstraZeneca Pharma India Limited has applied for the withdrawal of Olaparib Tablets in 100mg and 150mg dosages for the treatment of patients with gBRCA mutation and advanced ovarian cancer who have previously been treated with three or more lines of chemotherapy. This decision comes after a post hoc subgroup analysis indicated a potential detrimental effect on overall survival when comparing Olaparib to the chemotherapy control arm in this specific patient subgroup.

Following a thorough review in consultation with SEC Oncology experts during meetings held on March 19 and 20, 2024, at the Central Drugs Standard Control Organization (CDSCO), the decision was made to withdraw these specific indications for Olaparib tablets. The firm presented clinical evidence supporting this withdrawal, leading to the DCGI's directive for manufacturers to cease marketing Olaparib Tablets in 100mg and 150mg for the mentioned conditions and to submit a revised package insert.

Olaparib Tablets were initially approved by the DCGI on August 13, 2018, for the treatment of adult patients with ovarian cancer and certain forms of breast cancer. This recent directive underscores the commitment of health authorities to patient safety, ensuring that treatments available on the market are both effective and safe for their intended use.

This development is a reminder of the dynamic nature of pharmaceutical approvals, where ongoing research and post-marketing surveillance play crucial roles in determining the safety profile of drugs. As such, it highlights the importance of regulatory bodies in monitoring drug efficacy and safety to protect public health.